[质母细胞瘤管理的前景]
Nicolas Crainic1, Renata Ursu1, Stefania Cuzzubbo1
1Service de neurologie, AP-HP Nord-Université de Paris, site Saint-Louis, Paris, France.
La Revue du praticien
|October 23, 2025
概括
质母细胞瘤的治疗包括手术,辐射和temozolomide. 新兴的治疗方法,如瘤治疗场 (TTF) 提供延长生存,但需要不断使用和监测,突出早期支持性护理的需要.
科学领域:
- 神经瘤学神经瘤学
- 中枢神经系统恶性瘤 中枢神经系统恶性瘤
背景情况:
- 质母细胞瘤是最常见的原发性恶性脑瘤.
- 标准治疗包括手术,放射化疗和temozolomide.
研究的目的:
- 概述目前和新兴的质母细胞瘤管理策略.
- 强调对质母细胞瘤患者的监测和支持性护理的重要性.
主要方法:
- 对标准质母细胞瘤治疗方案的审查.
- 包括新兴疗法,如瘤治疗场 (TTF).
- 讨论神经瘤监测和支持性护理.
主要成果:
- 标准治疗包括使用temozolomide的多式疗法.
- 瘤治疗场 (TTF) 将中位生存时间延长到20个月,但有副作用.
- 由于不可避免的进展,密切监测和早期支持性护理至关重要.
结论:
- 质母细胞瘤的治疗需要采用多学科的方法.
- 对于进展性疾病存在有限的选择.
- 早期的支持性护理对于改善患者的生活质量至关重要.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...